114798-26-4 Losartan AKSci I497
 
 
Loading Please Wait...
  I497    AKSci Reference Standard
Losartan, >98% (HPLC), powder
 
Hyzaar
Cozaar
IDENTITY
CAS Number:114798-26-4
MDL Number:MFCD00865831
MF:C22H23ClN6O
MW:422.91
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>98% (HPLC), powder
Spectra:NMR, LCMS, HPLC
Physical Form (at 20°C):White to yellow powder
Melting Point:183.5°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:MeOH: 12mg/mL; DMSO: 20mg/mL, H20: insoluble
Application(s):Angiotensin-receptor blocker (ARB)

REVIEW
 Losartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion. Losartan is effective for reducing blood pressure and may be used to treat essential hypertension, left ventricular hypertrophy and diabetic nephropathy.

REFERENCES
[1]Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003.
[2] Guo ZX, Qiu MC: [Losartan downregulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat] Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):403-8.
[3] Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21.
[4] Sica, D.A., Gehr, T.W.B., & Ghosh, S. (2005). Clinical pharmacokinetics of losartan. Clinical Pharmacokinetics, 44(8), 797-814. PMID: 16029066

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Danger

Hazard Statements
H315; H318; H330

Precautionary Statements
P260; P264; P271; P280; P284; P302+P352; P304+P340; P305+P351+P338; P310; P320; P332+P313; P362; P403+P233; P405; P501

RELATED PRODUCTS
I497Losartan
I934Losartan potassium
I971Trityl losartan

Current as of January 29, 2022

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.


CATEGORIES
 APIs and Bioactives > Angiotensin Receptor Blockers


PubChem